Mayo Clinic News Network

News Resources

Paul Scotti (@pscotti)

Activity by Paul Scotti

Paul Scotti (@pscotti) posted · Fri, Sep 12 1:22pm · View  

Physicians Find Liver Transplant Patients Can Avoid Costly Stay In ICU Post Surgery

JACKSONVILLE, Fla., Sept. 12, 2014 — The liver transplant team at Mayo Clinic in Florida has found, based on 12 years of experience, that more than half of patients receiving a new liver can be “fast-tracked” to return to a surgical ward room following their transplant, bypassing a one- or two-day stay in the Intensive Care Unit (ICU).

In the September issue of the American Journal of Transplantation, the physicians and researchers have turned their knowledge of who can be safely fast-tracked into a scoring system that other transplant centers can also use — thus sparing patients potentially overly aggressive treatment and saving substantial health care dollars.

MEDIA CONTACT: Paul Scotti, Mayo Clinic Public Affairs, 904-953-0199. Email: scotti.paul@mayo.edu

[...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Tue, Sep 2 9:00am · View  

Mayo Clinic, University of North Florida Host Tenth Annual Upbeat Pink: A Musical Tribute to Breast Cancer Survivorship

JACKSONVILLE, Fla., Sept. 2, 2014 – Mayo Clinic and the University of North Florida are honoring Upbeat Pink ConcertNational Breast Cancer Awareness Month in October by hosting the tenth annual “Upbeat Pink: A Musical Tribute to Breast Cancer Survivorship” concert on Friday, Oct. 10 at 7:30 p.m. in Lazzara Performance Hall, UNF Fine Arts Building on the university’s campus in Jacksonville. The Upbeat Pink concert is free and open to the public.

The theme for this year’s program, “Dancing with the Survivors,” showcases a variety of dance music performed by the UNF Wind Symphony, conducted by Gordon Brock, D.M.A., and features special guest artist and multi-instrumentalist,  Bill Prince, D.M.A.

Guest speakers will include Laura Vallow, M.D., radiation oncologist at Mayo Clinic and Dianne Wagner, a local breast cancer survivor.
[...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Thu, Jun 5 2:35pm · View  

Estudo ALTTO sobre terapia combinada anti HER2, no Câncer de Mama, indica que um único agente, o Trastuzumabe, permanece como o padrão ouro de tratamento

CHICAGO — No maior estudo clínico já realizado para analisar a eficácia do tratamento do câncer de mama HER2 positivo, com um ou com a combinação de dois medicamentos, os pesquisadores relataram que o uso do lapatinibe (Tykerb) não apresentou  benefício ao tratamento auxiliar padrão com trastuzumabe (Herceptin), conforme apresentado durante o  50º encontro anual da Sociedade Americana de Oncologia Clínica (ASCO — American Society of Clinical Oncology).

Resultados do estudo clínico de fase III ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Study) demonstraram que ao acrescentar lapatinibe ao tratamento com trastuzimabe e quimioterapia não melhorou os resultados gerais para os pacientes (definidos como sobrevida livre da doença ou sobrevida total) e que o uso de lapatinibe aumentou de forma significativa a toxicidade do tratamento. [...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Thu, Jun 5 2:12pm · View  

Cáncer de mama: Estudio ALTTO sobre terapia combinada anti HER2, encuentra que agente único — el Trastuzumab — sigue siendo el mejor tratamiento estándar

CHICAGO — En el mayor estudio clínico que prueba la eficacia de un tratamiento versus dos drogas para tratar el cáncer de mama HER2-positivo, lapatinib (Tykerb ) no agregó beneficio en relación a la terapia adyuvante estándar, trastuzumab (Herceptin), según informan investigadores de la 50a reunión anual de la Sociedad Americana de Oncología Clínica (ASCO).

Los resultados del ensayo clínico de fase III, ALTTO (Estudio de Optimización de Tratamiento Adyuvante Lapatinib y/o Trastuzumab), demostraron que agregando lapatinib a trastuzumab y quimioterapia no mejoró el resultado del paciente (definido como supervivencia libre de enfermedad o supervivencia sin progresión de ésta),  y que el uso de lapatinib incrementó significativamente la toxicidad del tratamiento. [...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Thu, Jun 5 10:53am · View  

Tamanho do tumor é fator determinante para resposta a tratamento com medicamento promissor para tratamento de melanoma

CHICAGO — Ao examinar porque alguns pacientes com melanoma avançado respondem tão bem à imunoterapia experimental MK-3475, enquanto outros obtêm uma resposta mais fraca, pesquisadores da Clínica Mayo de Jacksonville, na Flórida, descobriram que o tamanho dos tumores, antes do tratamento, era a variável mais forte. [...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Thu, Jun 5 10:47am · View  

Tamaño del tumor es factor determinante en la respuesta a una promisoria droga para tratar el melanoma

CHICAGO —Al examinar por qué algunos pacientes con melanoma avanzado responden tan bien a la inmunoterapia experimental MK-3475, mientras que otros tienen una respuesta menos sólida, los investigadores de la Clínica Mayo en Jacksonville, Flórida, descubrieron que el tamaño de los tumores, antes del tratamiento, era la variable más importante. [...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Sun, Jun 1 7:30am · View  

ALTTO Test of Dual HER2 Blockade Finds Single Agent - Trastuzumab - Remains Gold Standard

Journalists: Broadcast soundbites with Dr. Perez are available in the downloads.

CHICAGO — In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib (Tykerb) did not add benefit to the standard trastuzumab (Herceptin) adjuvant therapy, researchers report at the 50th annual meeting of the American Society of Clinical Oncology (ASCO).

Results of the phase III clinical trial, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization study), demonstrated that adding lapatinib to trastuzumab and chemotherapy did not improve patient outcome (defined as disease-free survival or overall survival), and that use of lapatinib significantly increased toxicity.

“These findings suggest that standard adjuvant (post-surgery) treatment for early stage HER2-positive breast cancer should remain trastuzumab in combination with chemotherapy,” says Edith A. Perez, M.D., deputy director at large of the Mayo Clinic Cancer Center, and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida.
[...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Fri, May 30 3:23pm · View  

Tumor Size is Defining Factor to Response from Promising Melanoma Drug

CHICAGO — In examining why some advanced melanoma patients respond so well to the experimental immunotherapy MK-3475, while others have a less robust response, researchers at Mayo Clinic in Florida found that the size of tumors before treatment was the strongest variable.

They say their findings, being presented June 2 at the 50th annual meeting of the American Society of Clinical Oncology (ASCO), offered several clinical insights that could lead to different treatment strategies and perhaps influence staging of advanced melanoma.

“This was the first robust assessment to determine the impact of baseline tumor size on clinical endpoints in patients with metastatic melanoma — in particular — those receiving MK-3475. Our findings suggest the location of spread is less important than the amount of tumor that is present before treatment,” says the study’s lead investigator, Richard W. Joseph, M.D., an oncologist at Mayo Clinic in Florida.

Journalists: Broadcast sound bites with Dr. Joseph are available in the downloads.

 

[...]

Click here to view the rest of the post

Login here to comment.

Load More    

Loading information...